Epigenic Therapeutics: Valuation, Funding & Investors
Epigenic Therapeutics is a pioneering biotechnology company focused on developing next-generation gene modulation therapies through the regulation of the epigenetic genome. Utilizing its proprietary EPIREG(TM) technology platform, Epigenic offers innovative therapeutic solutions that provide efficient, durable, and specific gene silencing without the safety concerns associated with traditional gene-editing tools. The company is advancing a diverse pipeline of product candidates targeting metabolic, cardiovascular, viral hepatitis, ocular, and autoimmune diseases, leveraging its EpiTax(TM) delivery platform and AIAID(TM) platform for precise epigenetic modulation.
Leadership & Board
Latest Estimated Valuation
- Total Amount Raised
- $60M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $60M
- Latest Funding Round
- Series B
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Sep 08, 2025 | Series B | $60.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| OrbiMed | Series B |
| Qiming Venture Partners | Series B |
| Lapam Capital | Series B |
| IFSC | Series B |
Similar Companies
A snapshot of private companies similar to Epigenic Therapeutics, helping you discover and navigate related company profiles.
Related News and Analysis
